🔗 Visit the ClinicalTrials.gov page for NCT04036721
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | N Engl J Med | 2015 | 12.54 |
| 2 | An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. | Am J Respir Crit Care Med | 2013 | 6.82 |
| 3 | Cryptogenic organising pneumonia. | Eur Respir J | 2006 | 3.76 |
| 4 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Lancet | 2016 | 2.25 |
| 5 | Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | J Clin Oncol | 2016 | 1.06 |
| 6 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | 0.75 |
| 7 | Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. | Eur Respir J | 2017 | 0.75 |